

Review

Bone loss

Factors that regulate osteoclast differentiation: an update

Sophie Roux* and Philippe Orcel†

*†Lariboisière Hospital, Paris, and *Bicêtre Hospital, Bicêtre, France

Received: 8 March 2000
Revisions requested: 29 June 2000
Revisions received: 7 August 2000
Accepted: 14 August 2000
Published: 6 September 2000

Arthritis Res 2000, 2:451–456

© Current Science Ltd (Print ISSN 1465-9905; Online ISSN 1465-9913)

Abstract

Osteoclast activation is a critical cellular process for pathological bone resorption, such as erosions in rheumatoid arthritis (RA) or generalized bone loss. Among many factors triggering excessive osteoclast activity, cytokines such as IL-1 or tumour necrosis factor (TNF)- α play a central role. New members of the TNF receptor ligand family (namely receptor activator of nuclear factor- κ B [RANK] and RANK ligand [RANKL]) have been discovered whose cross-interaction is mandatory for the differentiation of osteoclasts from hemopoietic precursors, in both physiological and pathological situations. Osteoprotegerin, a decoy receptor which blocks this interaction, decreases osteoclast activity and could have a fascinating therapeutic potential in conditions associated with upregulated bone resorption.

Keywords: bone cytokines, differentiation, osteoclast, osteoprotegerin, RANK, RANKL

Introduction

Bone remodelling is a continuous physiological process that occurs in adult skeleton in which bone resorption is followed by new bone formation, maintaining mechanical strength and structure. Bone cells that are responsible for this coupled process include bone-resorbing cells (osteoclasts, which are derived from haematopoietic cells of the monocyte/macrophage lineage) and bone-forming cells (osteoblasts, which are of mesenchymal origin). The bone resorption process is involved in many clinical situations that are relevant to the work of rheumatologists, such as

focal bone destruction or erosion in RA and other inflammatory arthritides, and the diffuse bone loss that is encountered in osteoporosis.

Osteoclast differentiation: basic mechanisms and new insights

Osteoclast progenitor cells are recruited from haematopoietic compartments, and then proliferate and differentiate toward mature osteoclasts. During this multistep differentiation process postmitotic osteoclast precursors progressively express osteoclast-associated markers, such

M-CSF = macrophage colony-stimulating factor; NF- κ B = nuclear factor- κ B; ODF = osteoclast differentiation factor; 1,25(OH) $_2$ D $_3$ = 1,25-dihydroxy-vitamin D $_3$; PTH = parathyroid hormone; RA = rheumatoid arthritis; RANK = receptor activator of nuclear factor- κ B; RANKL = receptor activator of nuclear factor- κ B ligand; TNF = tumour necrosis factor.

as calcitonin receptor and tartrate-resistant acid phosphatase, as they lose some of their macrophage characteristics. Then, mononuclear preosteoclasts fuse together to form multinucleated giant cells. Terminal osteoclast differentiation eventually leads to active bone-resorbing cells [1].

Role of osteoblast/stromal cells in osteoclast differentiation

Biological models of *in vitro* osteoclast differentiation have been developed that have facilitated detailed study of many of the factors involved in the regulation of this process. The most commonly studied models are cultures of mouse bone marrow or cocultures of haematopoietic cells with bone-derived stromal cells, which give rise to large numbers of bone-resorbing osteoclasts [2]. Studies based on these models have found that mesenchymally derived stromal cells play a critical role in supporting and stimulating osteoclast differentiation, a process that probably necessitates cell–cell contact between osteoclast precursors and stromal cells [3,4]. In some human models, however, a cellular interaction between osteoclast precursors and stromal cells is not always required [5–7].

Local and hormonal factors that are involved in osteoclast differentiation

Bone resorption is closely controlled *in vivo* by cellular and hormonal factors, which affect not only osteoclast activity, but also osteoclast formation. Parathyroid hormone (PTH) and 1,25-dihydroxyvitamin D₃ [1,25(OH)₂D₃] increase bone resorption, primarily via an indirect mechanism that is mediated by osteoblasts [2]. Oestrogens have a negative impact on osteoclast differentiation, and oestrogen deficiency leads to increased osteoclast differentiation and activation [8]. The cytokines IL-1, IL-6 and TNF- α are known to increase bone resorption by stimulating both osteoclast activity and differentiation. This effect involves, at least in part, prostaglandin production [9,10]. The major role of macrophage colony-stimulating factor (M-CSF) has been pointed out in M-CSF-deficient (*op/op*) mice, which develop an osteopetrosis that is characterized by the absence of osteoclasts [11]. Studies using murine cocultures [12] have shown that M-CSF acts both on proliferation and on differentiation of precursor cells. Local injections of M-CSF in rat metaphyseal bone also increase *in situ* osteoclast differentiation and bone resorption [13]. Other cytokines stimulate bone resorption at least partly by increasing osteoclast differentiation, such as leukaemia inhibiting factor and IL-11 [14,15]. Conversely, some cytokines such as IL-4 or IFN- γ have been shown to inhibit osteoclast differentiation *in vitro* [16]. The role of transforming growth factor- β is more complex; it decreases osteoclast precursor proliferation and bone resorption activity [17,18], but it also increases the expression of two osteoclastic markers – vitronectin receptor and calcitonin receptor [19,20]. Most of the cytokines that regulate osteoclast differentiation are produced in the bone

microenvironment, mainly by osteoblast/stromal cells, further emphasizing the key role of these cells in osteoclast differentiation.

A new interactive system in osteoclast bone resorption

The recent discovery of new members of the TNF receptor ligand family has pointed out the crucial role of RANK and RANKL in osteoclast differentiation and activation [21*, 22*] (Fig. 1).

RANKL, also called osteoclast differentiation factor (ODF), TNF-related induced cytokine (TRANCE), or osteoprotegerin ligand (OPGL)


Because osteoblast–stromal cell interactions with osteoclast precursors are required for subsequent osteoclast differentiation, an ODF expressed by these cells and recognized by osteoclast precursors was suspected. Such a factor was identified as RANKL [23**,24**]. RANKL is a membrane-bound TNF-related factor that is expressed by osteoblast/stromal cells. That the presence of RANKL is vital in osteoclast differentiation is now well established, and its soluble recombinant form has been tested in a number of *in vitro* and *in vivo* studies. In *in vitro* murine or human osteoclast differentiation models, soluble RANKL enables osteoclast precursors to differentiate in the presence of M-CSF, even in the absence of osteoblast/stromal cells [25**,26]. Bone resorption activity is increased, as well as the osteoclast survival [23**,26]. Mice that are defective for RANKL develop a form of osteopetrosis. They are characterized by the absence of osteoclasts, although osteoclast progenitors are present and are able to differentiate into bone-resorbing osteoclasts in the presence of normal osteoblast/stromal cells [27**].

In addition, the soluble form of RANKL has been shown to be produced by human fibroblasts transfected with an expression vector for RANKL and by *in vitro* activated murine T cells [23**,28]. However, it is not clear whether this soluble form plays a role *in vivo* in normal bone homeostasis or in pathological processes that are characterized by increased bone resorption.

RANK

Osteoclast precursors express RANK, a membrane-bound TNF receptor that recognizes RANKL through a direct cell–cell interaction with osteoblast/stromal cells [29**]. Recent studies [29**,30] demonstrated that this receptor is essential for the transduction of signals that lead to osteoclast differentiation. An overexpression of soluble RANK results in osteopetrosis, with a decreased number of osteoclasts [30]. Conversely, mice that are deficient for RANK develop a severe osteopetrosis that is characterized by the absence of osteoclasts. In addition, osteoclast precursors in these mice are unable to differentiate to osteoclasts *in vitro*, in the presence of RANKL and M-CSF [31].

Figure 1



New members of the TNF receptor ligand family: role of RANKL (ODF, TRANCE, OPGL) and its receptor RANK in osteoclast differentiation. RANKL, a membrane-bound TNF-related factor, is expressed by osteoblast/stromal cells and is upregulated by osteotropic factors such as 1,25(OH)₂D₃, PTH, IL-6 or IL-11. Osteoclast (OC) precursors express RANK, a membrane-bound TNF receptor, that recognizes RANKL through cell-cell interaction with osteoblast/stromal cells. This interaction enables osteoclast precursors to differentiate in the presence of M-CSF. Osteoprotegerin (OPG) is a member of the TNF receptor family that lacks a transmembrane domain and represents a secreted TNF receptor. OPG recognizes RANKL, and this decoy receptor blocks the interaction between RANK and RANKL, leading to inhibition of osteoclast differentiation and activation.

Osteoprotegerin

Osteoprotegerin is a member of the TNF receptor family that lacks a transmembrane domain and represents a secreted receptor. Osteoprotegerin recognizes RANKL, and this decoy receptor blocks the interaction between RANK and RANKL, leading to an inhibition of osteoclast differentiation and activation [32^{**},33^{**}]. Overexpression of osteoprotegerin in transgenic mice results in a form of osteopetrosis that is characterized by a defect in osteoclast differentiation [32^{**}]. By contrast, osteoprotegerin-deficient mice develop severe osteoporosis because of increased osteoclast differentiation and function [34^{**}]. *In vitro* studies have demonstrated the strong inhibitory action of osteoprotegerin on osteoclast differentiation, as well as on the bone-resorbing activity of osteoclasts [32^{**},33^{**}].

Role of RANK/RANKL and osteoprotegerin in osteoclast differentiation

RANKL/osteoprotegerin balance, signal transduction and osteoclast differentiation

Recent data suggest that M-CSF and RANKL are two major factors involved in osteoclast differentiation. M-CSF is required for both proliferation and differentiation, and RANKL (which is not a growth factor) is required for differentiation into mature osteoclasts and for osteoclast activity [26]. In bone tissue, osteoprotegerin and RANKL are

expressed by osteoblast/stromal cells, and the ratio of these products may modulate the ability of these cells to stimulate osteoclast differentiation/activity, as well as the rate of bone resorption [21^{*}].

In addition, it has been shown [26] that the interaction between RANKL and RANK results in a transduction signal in preosteoclasts and in mature osteoclasts that may activate nuclear factor-κ (NF-κB). The role of NF-κB in the osteoclast differentiation has been previously demonstrated in mice with a double knockout for the p50 and p52 NF-κB subunits, in which a defect of osteoclast differentiation leads to an osteopetrosis [35,36]. Other intracellular events are activated by transduction signals, such as *c-jun* terminal kinase, and TNF receptor-associated factors, which regulate activation of NF-κB and/or *c-jun* terminal kinase [21^{*}].

RANK/RANKL, immune cells and osteoclast differentiation

RANK and RANKL have been shown to be expressed in dendritic cells and T lymphocytes, respectively, in which they appear to be important regulators of the interactions between these cells [37,38]. These data suggest that, apart from osteoclast differentiation and activation, RANK and RANKL are involved in the immune system as suggested by the mice knockout models. RANKL-deficient mice lack lymph nodes and exhibit defects in differentiation of T and B lymphocytes [27^{**}], and RANK-deficient mice exhibit a marked deficiency in B cells in the spleen and lack lymph nodes [31].

Regulation of RANKL and osteoprotegerin expression

Recent studies have demonstrated that osteotropic factors and hormones such as PTH, 1,25(OH)₂D₃, IL-11, IL-1β, TNF-α or prostaglandin E₂ upregulate RANKL expression in osteoblast/stromal cells (Fig. 1). In addition, osteoprotegerin expression is downregulated by prostaglandin E₂, and is upregulated by oestrogens [21^{*}]. RANK expression has not yet been extensively studied.

An integrated view and clinical implications

An emerging concept is that cytokines and hormonal factors that are involved in bone resorption may act by a common final pathway involving RANKL and RANK [21^{*}]. In accordance with this concept, a recent *in vivo* study [39^{**}] has shown that a recombinant chimaeric Fc fusion form of osteoprotegerin inhibited hypercalcaemia and bone resorption induced by IL-1β, TNF-α, PTH and 1,25(OH)₂D₃ in mice. This convergence theory is probably not exclusive because recent studies [40,41] have suggested that the effects of TNF-α or IL-6 may involve different effectors.

Therapeutic perspectives

The concept presented above will probably lead to new therapeutic approaches in several diseases that are characterized by excessive bone resorption. Thus, osteoprote-

gerin (a specific inhibitor of RANKL) or an analogue may be used to block the excess of bone resorption in pathological conditions such as hyper-resorption of malignancy, in which this pathway seems to be primarily involved [42**], or in osteoporosis, in which oestrogen deficiency could lead to decreased production of osteoprotegerin and subsequent increased bone resorption.

Bone erosions in rheumatoid arthritis

Rheumatoid arthritis is another interesting clinical model for the study of the role of RANK/RANKL in bone erosions, and as a therapeutic target for osteoprotegerin. Rheumatoid arthritis is characterized by progressive bone and cartilage destruction as a result of chronic synovitis. Numerous studies have pointed out the role of cytokines such as TNF- α or IL-1 in the joint destruction [43]. Recent studies suggest that RANKL mRNA is highly expressed in synovial tissues from patients with RA, but not in normal synovial tissues. This expression is detected in synovial fibroblasts, as well as in activated T cells derived from RA synovial tissues, suggesting that these cells may contribute to osteoclast formation at the specific sites of bone destruction in RA [44*,45*]. In addition, in rat adjuvant-induced arthritis, RANKL is expressed on the surface of activated T cells isolated from affected rats, and may be secreted in T cell cultures. Activated T cells could therefore directly induce osteoclastogenesis through membrane-bound and soluble RANKL [28]. These data suggest that RANKL may have a major pathophysiological importance in the bone and joint destruction observed in inflammatory arthritides such as RA. Activated T cells, which play a central role in the pathogenesis of RA, may (in addition to stromal cells) contribute to the osteoclast-mediated bone resorption via RANKL expression [46**].

Conclusion

Osteoclasts are multinucleated cells that are formed by fusion of osteoclast precursors from haematopoietic origin. These cells are responsible for bone resorption and osteoclast differentiation and represent an evident point of control of bone resorption. Bone resorption is closely regulated *in vivo* by many cellular and hormonal factors, which affect not only osteoclast activity, but also osteoclast formation. The recent discovery of new members of the TNF receptor ligand family (ODF, TNF-related induced cytokine, osteoprotegerin ligand) have emphasized the crucial role of RANKL, which is expressed by osteoblast/stromal cells, and its receptor RANK, which is expressed by osteoclast cells, in osteoclast differentiation and activation. This system is completed by osteoprotegerin, which is a secreted TNF receptor. Osteoprotegerin recognizes RANKL, and this decoy receptor blocks the interaction between RANK and RANKL. A number of osteotropic factors and hormones may modulate bone resorption via this common final pathway, which may represent a potential therapeutic

target in pathologic processes that are characterized by excessive bone resorption.

References

Articles of particular interest have been highlighted as:

- of special interest
 - of outstanding interest
1. Takahashi N, Udagawa N, Tanaka S, Murakami H, Owan I, Tamura T, Suda T: **Postmitotic osteoclast precursors are mononuclear cells which express macrophage-associated phenotypes.** *Dev Biol* 1994, **163**:212-221.
 2. Suda T, Takahashi N, Martin TJ: **Modulation of osteoclast differentiation.** *Endocr Rev* 1992, **13**:66-80.
 3. Takahashi N, Akatsu T, Udagawa N, Sasaki T, Yamaguchi A, Moseley JM, Martin TJ, Suda T: **Osteoblastic cells are involved in osteoclast formation.** *Endocrinology* 1988, **123**:2600-2602.
 4. Quinn JM, McGee JO, Athanasou NA: **Cellular and hormonal factors influencing monocyte differentiation to osteoclastic bone-resorbing cells.** *Endocrinology* 1994, **134**:2416-2423.
 5. Kurihara N, Civin C, Roodman GD: **Osteotropic factor responsiveness of highly purified populations of early and late precursors for human multinucleated cells expressing the osteoclast phenotype.** *J Bone Miner Res* 1991, **6**:257-261.
 6. Matayoshi A, Brown C, DiPersio JF, Haug J, Abu-Amer Y, Liapis H, Kuestner R, Pacifici R: **Human blood-mobilized hematopoietic precursors differentiate into osteoclasts in the absence of stromal cells.** *Proc Natl Acad Sci USA* 1996, **93**:10785-10790.
 7. Roux S, Quinn J, Pichaud F, Orcel P, Chastre E, Jullienne A, De Vernejoul MC: **Human cord blood monocytes undergo terminal osteoclast differentiation in vitro in the presence of culture medium conditioned by giant cell tumor of bone.** *J Cell Physiol* 1996, **168**:489-498.
 8. de Vernejoul MC, Cohen-Solal M, Orcel P: **Bone cytokines.** *Curr Opin Rheumatol* 1993, **5**:332-338.
 9. Roodman GD: **Interleukin-6: an osteotropic factor?** *J Bone Miner Res* 1992, **7**:475-478.
 10. Pfeilschifter J, Chenu C, Bird A, Mundy GR, Roodman GD: **Interleukin-1 and tumor necrosis factor stimulate the formation of human osteoclastlike cells in vitro.** *J Bone Miner Res* 1989, **4**:113-118.
 11. Yoshida H, Hayashi S, Kunisada T, Ogawa M, Nishikawa S, Okamura H, Sudo T, Shultz LD, Nishikawa S: **The murine mutation osteopetrosis is in the coding region of macrophage colony stimulating factor gene.** *Nature* 1990, **345**:442-444.
 12. Tanaka S, Takahashi N, Udagawa N, Tamura T, Akatsu T, Stanley ER, Kurokawa T, Suda T: **Macrophage colony-stimulating factor is indispensable for both proliferation and differentiation of osteoclast progenitors.** *J Clin Invest* 1993, **91**:257-263.
 13. Orcel P, Feuga M, Bielakoff J, de Vernejoul MC: **Local bone injections of LPS and M-CSF increase bone resorption by different pathways in vivo in rats.** *Am J Physiol* 1993, **264**:E391-E397.
 14. Ishimi Y, Abe E, Jin CH, Miyaura C, Hong MH, Oshida M, Kurosawa H, Yamaguchi Y, Tomida M, Hozumi M: **Leukemia inhibitory factor/ differentiation-stimulating factor (LIF/D-Factor): regulation of its production and possible roles in bone metabolism.** *J Cell Physiol* 1992, **152**:71-78.
 15. Girasole G, Passeri G, Jilka RL, Manolagas SC: **Interleukin-11: a new cytokine critical for osteoclast development.** *J Clin Invest* 1994, **93**:1516-1524.

16. Lacey DL, Erdmann JM, Teitelbaum SL, Tan H, Ohara J, Shioi A: **Interleukin 4, Interferon- γ and prostaglandin E impact the osteoclast cell-forming potential of murine bone marrow macrophages.** *Endocrinology* 1995, **136**:2367–2376.
17. Oreffo RO, Bonewald L, Kukita A, Garrett IR, Seyedin SM, Rosen D, Mundy GR: **Inhibitory effects of bone-derived growth factors, osteoinductive factor and transforming growth factor- β on isolated osteoclasts.** *Endocrinology* 1990, **126**:3069–3075.
18. Chenu C, Pfeilschifter J, Mundy GR, Roodman GD: **Transforming growth factor β inhibits formation of osteoclast-like cells in long-term human marrow cultures.** *Proc Natl Acad Sci USA* 1988, **85**:5683–5687.
19. Mbalaviele G, Orcel P, Bouizar Z, Julienne A, de Vernejoul MC: **Transforming growth factor β enhances calcitonin-induced cyclic AMP production and the number of calcitonin receptors in long term cultures of human umbilical cord blood monocytes in the presence of 1,25-dihydroxycholecalciferol.** *J Cell Physiol* 1992, **152**:486–494.
20. Orcel P, Bielakoff J, de Vernejoul MC: **Effect of transforming growth factor β on long-term human cord blood monocytes cultures.** *J Cell Physiol* 1990, **142**:293–298.
21. Hofbauer LC, Khosla S, Dunstan CR, Lacey DL, Boyle WJ, Riggs BL: **The roles of osteoprotegerin and osteoprotegerin ligand in the paracrine regulation of bone resorption.** *J Bone Miner Res* 2000, **15**:2–12.

This review concerns RANKL, RANK and osteoprotegerin. Osteoclast differentiation may be determined by the relative ratio of RANKL to osteoprotegerin in the bone marrow microenvironment. These factors mediate the effects of large numbers of upstream hormones and cytokines, suggesting a final common pathway in the regulation of osteoclastogenesis.
22. Suda T, Takahashi N, Udagawa N, Jimi E, Gillespie MT, Martin TJ: **Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families.** *Endocr Rev* 1999, **20**:345–357.

This review concerns RANKL, RANK and osteoprotegerin – three key molecules that regulate osteoclast recruitment and function.
23. Lacey DL, Timms E, Tan HL, Kelley MJ, Dunstan CR, Burgess T, Elliott R, Colombero A, Elliott G, Scully S, Hsu H, Sullivan J, Hawkins N, Davy E, Capparelli C, Eli A, Qian YX, Kaufman S, Sarosi I, Shalhoub V, Senaldi G, Guo J, Delaney J, Boyle WJ: **Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation.** *Cell* 1998, **93**:165–176.

The identification and cloning of the ligand of osteoprotegerin from a murine myelomonocytic cell line is discussed. Data are presented that suggest that OPGL is an osteoclast differentiation and activation factor.
24. Yasuda H, Shima N, Nakagawa N, Yamaguchi K, Kinosaki M, Mochizuki S, Tomoyasu A, Yano K, Goto M, Murakami A, Tsuda E, Morinaga T, Higashio K, Udagawa N, Takahashi N, Suda T: **Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL.** *Proc Natl Acad Sci USA* 1998, **95**:3597–3602.

This paper describes the identification and cloning of the ligand of osteoprotegerin, ODF, from mouse stromal cell ST2. ODF mediates an essential signal to osteoclast progenitors for their differentiation into osteoclasts.
25. Quinn JM, Elliott J, Gillespie MT, Martin TJ: **A combination of osteoclast differentiation factor and macrophage-colony stimulating factor is sufficient for both human and mouse osteoclast formation in vitro.** *Endocrinology* 1998, **139**:4424–4427.

This study demonstrates that murine and human osteoclast precursors, when cultured in the presence of M-CSF and a soluble form of murine ODF, form bone-resorbing osteoclasts in the absence of osteoblast/stromal cells.
26. Jimi E, Akiyama S, Tsurukai T, Okahashi N, Kobayashi K, Udagawa N, Nishihara T, Takahashi N, Suda T: **Osteoclast differentiation factor acts as a multifunctional regulator in murine osteoclast differentiation and function.** *J Immunol* 1999, **163**:434–442.
27. Kong YY, Yoshida H, Sarosi I, Tan HL, Timms E, Capparelli C, Morony S, Oliveira-dos-Santos AJ, Van G, Itie A, Khoo W, Wakeham A, Dunstan CR, Lacey DL, Mak TW, Boyle WJ, Penninger JM: **OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis.** *Nature* 1999, **397**:315–323.

Osteoprotegerin ligand-deficient mice develop severe osteopetrosis and a defect in tooth eruption, and completely lack osteoclasts as a result of an inability of osteoblasts to support osteoclastogenesis.
28. Kong YY, Feige U, Sarosi I, Bolon B, Tafuri A, Morony S, Capparelli C, Li J, Elliott R, McCabe S, Wong T, Campagnuolo G, Moran E, Bogoch ER, Van G, Nguyen LT, Ohashi PS, Lacey DL, Fish E, Boyle WJ, Penninger JM: **Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand.** *Nature* 1999, **402**:304–309.
29. Nakagawa N, Kinosaki M, Yamaguchi K, Shima N, Yasuda H, Yano K, Morinaga T, Higashio K: **RANK is the essential signaling receptor for osteoclast differentiation factor in osteoclastogenesis.** *Biochem Biophys Res Commun* 1998, **253**:395–400.

This paper describes the cloning of ODF receptor, RANK, from a mouse macrophage-like osteoclast progenitor cell line.
30. Hsu H, Lacey DL, Dunstan CR, Solovyev I, Colombero A, Timms E, Tan HL, Elliott G, Kelley MJ, Sarosi I, Wang L, Xia XZ, Elliott R, Chiu L, Black T, Scully S, Capparelli C, Morony S, Shimamoto G, Bass MB, Boyle WJ: **Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand.** *Proc Natl Acad Sci USA* 1999, **96**:3540–3545.
31. Dougall WC, Glaccum M, Charrier K, Rohrbach K, Brasel K, De Smedt T, Daro E, Smith J, Tometsko ME, Maliszewski CR, Armstrong A, Shen V, Bain S, Cosman D, Anderson D, Morrissey PJ, Peschon JJ, Schuh J: **RANK is essential for osteoclast and lymph node development.** *Genes Dev* 1999, **13**:2412–2424.
32. Simonet WS, Lacey DL, Dunstan CR, Kelley M, Chang MS, Luthy R, NguyenHQ, Wooden S, Bennett L, Boone T, Shimamoto G, DeRose M, Elliott R, Colombero A, Tan HL, Trail G, Sullivan J, Davy E, Bucay N, Renshaw-Gegg L, Hughes TM, Hill D, Pattison W, Campbell P, Boyle WJ: **Osteoprotegerin: a novel secreted protein involved in the regulation of bone density.** *Cell* 1997, **89**:309–319.

This paper describes the identification of osteoprotegerin, a potent inhibitor of bone resorption, from a foetal rat intestine cDNA library. *In vivo*, over-expression of osteoprotegerin in transgenic mice or administration of recombinant osteoprotegerin into normal mice results in a severe osteopetrosis, secondary to a decrease in later stages of osteoclast differentiation.
33. Tsuda E, Goto M, Mochizuki S, Yano K, Kobayashi F, Morinaga T, Higashio K: **Isolation of a novel cytokine from human fibroblasts that specifically inhibits osteoclastogenesis.** *Biochem Biophys Res Commun* 1997, **234**:137–142.

Identification of osteoclastogenesis inhibitory factor from human embryonic lung fibroblasts is described. This factor, which is identical to osteoprotegerin, inhibits osteoclast-like cell formation stimulated through three distinct signalling pathways involving $1\alpha,25$ -dihydroxyvitamin D_3 , PTH or IL-11.
34. Bucay N, Sarosi I, Dunstan CR, Morony S, Tarpley J, Capparelli C, Scully S, Tan HL, Xu W, Lacey DL, Boyle WJ, Simonet WS: **Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification.** *Genes Dev* 1998, **12**:1260–1268.

Osteoprotegerin-deficient mice develop an osteoporosis that is characterized by severe trabecular and cortical bone porosity, marked thinning of the parietal bones of the skull, and a high incidence of fractures. Osteoprotegerin-deficient mice also exhibit medial calcification of the aorta and renal arteries.
35. Franzoso G, Carlson L, Xing L, Poljak L, Shores EW, Brown KD, Leonardi A, Tran T, Boyce BF, Siebenlist U: **Requirement for NF-kappaB in osteoclast and B-cell development.** *Genes Dev* 1997, **11**:3482–3496.
36. Iotsova V, Caamano J, Loy J, Yang Y, Lewin A, Bravo R: **Osteopetrosis in mice lacking NF-kappaB1 and NF-kappaB2.** *Nature Med* 1997, **3**:1285–1289.

37. Anderson DM, Maraskovsky E, Billingsley WL, Dougall WC, Tometsko ME, Roux ER, Teepe MC, DuBose RF, Cosman D, Galibert L: **A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function.** *Nature* 1997, **390**:175–179.
38. Wong BR, Rho J, Arron J, Robinson E, Orlinick J, Chao M, Kalachikov S, Cayani E, Bartlett FS 3rd, Frankel WN, Lee SY, Choi Y: **TRANCE is a novel ligand of the tumor necrosis factor receptor family that activates c-Jun N-terminal kinase in T cells.** *J Biol Chem* 1997, **272**:25190–25194.
39. Morony S, Capparelli C, Lee R, Shimamoto G, Boone T, Lacey DL, Dunstan CR: **A chimeric form of osteoprotegerin inhibits hypercalcaemia and bone resorption induced by IL-1beta, TNF-alpha, PTH, PTHrP, and 1, 25(OH)2D3.** *J Bone Miner Res* 1999, **14**:1478–1485.
In vivo administration of osteoprotegerin prevented bone resorption and hypercalcaemia induced by bone-resorbing factors (IL-1 β , TNF- α , PTH, PTH related-protein, and 1,25(OH) $_2$ D $_3$).
40. Hofbauer LC, Lacey DL, Dunstan CR, Spelsberg TC, Riggs BL, Khosla S: **Interleukin-1beta and tumor necrosis factor-alpha, but not interleukin-6, stimulate osteoprotegerin ligand gene expression in human osteoblastic cells.** *Bone* 1999, **25**:255–259.
41. Kobayashi K, Takahashi N, Jimi E, Udagawa N, Takami M, Kotake S, Nakagawa N, Kinoshita M, Yamaguchi K, Shima N, Yasuda H, Morinaga T, Higashio K, Martin TJ, Suda T: **Tumor necrosis factor alpha stimulates osteoclast differentiation by a mechanism independent of the ODF/RANKL-RANK interaction.** *J Exp Med* 2000, **191**:275–286.
42. Chikatsu N, Takeuchi Y, Tamura Y, Fukumoto S, Yano K, Tsuda E, Ogata E, Fujita T: **Interactions between cancer and bone marrow cells induce osteoclast differentiation factor expression and osteoclast-like cell formation in vitro.** *Biochem Biophys Res Commun* 2000, **267**:632–637.
Enhanced osteoclastogenesis in the presence of cancer cells might be due to an increase in ODF (RANKL) activity. The interactions between cancer cells and mouse bone marrow cells induce ODF expression and suppress osteoprotegerin level in bone metastases, resulting in increased local bone destruction.
43. Duff GW: **Cytokines and anti-cytokines.** *Br J Rheumatol* 1993, **32(Suppl 1)**:15–20.
44. Gravalles EM, Manning C, Tsay A, Naito A, Pan C, Amento E, Goldring SR: **Synovial tissue in rheumatoid arthritis is a source of osteoclast differentiation factor.** *Arthritis Rheum* 2000, **43**:250–258.
ODF (RANKL) is expressed in synovial tissues from RA but not in normal synovium. This expression is detected in cultured synovial fibroblasts and in activated T cells derived from RA synovial tissue.
45. Takayanagi H, Iizuka H, Juji T, Nakagawa T, Yamamoto A, Miyazaki T, Koshihara Y, Oda H, Nakamura K, Tanaka S: **Involvement of receptor activator of nuclear factor kappaB ligand/osteoclast differentiation factor in osteoclastogenesis from synoviocytes in rheumatoid arthritis.** *Arthritis Rheum* 2000, **43**:259–269.
RANKL is highly expressed in synovial tissues from RA, but not in normal synovium or in osteoarthritic synovium. Cultured rheumatoid synovial fibroblasts expressed RANKL and are able to induce osteoclast differentiation, which requires cell–cell contact between synovial cells and osteoclast precursors.
46. Horwood NJ, Kartsogiannis V, Quinn JM, Romas E, Martin TJ, Gillespie MT: **Activated T lymphocytes support osteoclast formation in vitro.** *Biochem Biophys Res Commun* 1999, **265**:144–150.
Human activated T lymphocytes produce RANKL. In addition, they support osteoclast differentiation in cocultures with murine spleen cells used as a source of osteoclast precursors.

Authors' affiliations: Sophie Roux and Philippe Orcel (INSERM U349, Lariboisière Hospital, Paris, France), Sophie Roux (Department of Rheumatology, Bicêtre Hospital, Bicêtre, France), and Philippe Orcel (Department of Rheumatology, Lariboisière Hospital, Paris, France)

Correspondence: Philippe Orcel, Professor of Rheumatology, MD, PhD, Department of Rheumatology, Lariboisière Hospital, Centre Viggo Petersen, 2, rue Ambroise Paré, 75475 Paris, France.
Tel: +33 1 4995 8825; fax: +33 1 4995 8631;
e-mail: philippe.orcel@lrb.ap-hop-paris.fr